Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer

BMC Cancer

Venkatakrishna Rao Jala¹  Brandie N Radde²  Bodduluri Haribabu¹  Carolyn M Klinge² 

[1] James Graham Brown Cancer Center, Department of Microbiology and Immunology, 505 South Hancock Street, Room 323, CTR Building, Louisville, KY 40202, USA

[2] Department of Biochemistry and Molecular Biology, and Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, KY, 40202, USA

关键词: Tissue microarray;    Immunohistochemistry;    Protein expression;    Lung cancer;    Estrogen receptor;    Estrogen;    GPR30;    GPER;   

Others  :  1079993
DOI  :  10.1186/1471-2407-12-624

 received in 2012-10-26, accepted in 2012-12-19,  发布年份 2012

【 摘 要 】

Background

G-protein-coupled estrogen receptor (GPER/GPR30) was reported to bind 17β-estradiol (E₂), tamoxifen, and ICI 182,780 (fulvestrant) and promotes activation of epidermal growth factor receptor (EGFR)-mediated signaling in breast, endometrial and thyroid cancer cells. Although lung adenocarcinomas express estrogen receptors α and β (ERα and ERβ), the expression of GPER in lung cancer has not been investigated. The purpose of this study was to examine the expression of GPER in lung cancer.

Methods

The expression patterns of GPER in various lung cancer lines and lung tumors were investigated using standard quantitative real time PCR (at mRNA levels), Western blot and immunohistochemistry (IHC) methods (at protein levels). The expression of GPER was scored and the pairwise comparisons (cancer vs adjacent tissues as well as cancer vs normal lung tissues) were performed.

Results

Analysis by real-time PCR and Western blotting revealed a significantly higher expression of GPER at both mRNA and protein levels in human non small cell lung cancer cell (NSCLC) lines relative to immortalized normal lung bronchial epithelial cells (HBECs). The virally immortalized human small airway epithelial cell line HPL1D showed higher expression than HBECs and similar expression to NSCLC cells. Immunohistochemical analysis of tissue sections of murine lung adenomas as well as human lung adenocarcinomas, squamous cell carcinomas and non-small cell lung carcinomas showed consistently higher expression of GPER in the tumor relative to the surrounding non-tumor tissue.

Conclusion

The results from this study demonstrate increased GPER expression in lung cancer cells and tumors compared to normal lung. Further evaluation of the function and regulation of GPER will be necessary to determine if GPER is a marker of lung cancer progression.

【 授权许可】

   
2012 Jala et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011. CA Cancer J Clin 2011, 61:212-236.
• [2]Ramchandran K, Patel JD: Sex Differences in Susceptibility to Carcinogens. Semin Oncol 2009, 36:516-523.
• [3]Kiyohara C, Ohno Y: Sex differences in lung cancer susceptibility: a review. Gender Medicine 2010, 7:381-401.
• [4]Bouchardy C, Benhamou S, Schaffar R, Verkooijen HM, Fioretta G, Schubert H, Vinh-Hung V, Soria J-C, Vlastos G, Rapiti E: Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer 2011, 117:1288-1295.
• [5]Dubey S, Siegfried JM, Traynor AM: Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol 2006, 7:416-424.
• [6]Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005, 70:372-381.
• [7]Drummond AE, Britt KL, Dyson M, Jones ME, Kerr JB, O'Donnell L, Simpson ER, Findlay JK: Ovarian steroid receptors and their role in ovarian function. Mol Cell Endocrinol 2002, 191:27-33.
• [8]O'Donnell L, Robertson KM, Jones ME, Simpson ER: Estrogen and spermatogenesis. Endocr Rev 2001, 22:289-318.
• [9]McEwen B: Estrogen actions throughout the brain. Recent Prog Horm Res 2002, 57:357-384.
• [10]Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282.
• [11]Townson SM, O'Connell P: Identification of estrogen receptor alpha variants in breast tumors: implications for predicting response to hormonal therapies. J Surg Oncol 2006, 94:271-273.
• [12]Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D: Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000, 2000:75-93.
• [13]Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA: Mechanisms of estrogen action. Physiol Rev 2001, 81:1535-1565.
• [14]Zhao C, Gao H, Liu Y, Papoutsi Z, Jaffrey S, Gustafsson J-Å, Dahlman-Wright K: Genome-Wide Mapping of Estrogen Receptor-β–Binding Regions Reveals Extensive Cross-Talk with Transcription Factor Activator Protein-1. Cancer Res 2010, 70:5174-5183.
• [15]Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V: Endocrine therapy of breast cancer. Curr Med Chem 2011, 18:513-522.
• [16]Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
• [17]Mollerup S, Jorgensen K, Berge G, Haugen A: Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002, 37:153-159.
• [18]Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002, 62:2141-2150.
• [19]Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65:1459-1470.
• [20]Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG, Klinge CM: Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 2006, 13:113-134.
• [21]Ivanova MM, Mazhawidza W, Dougherty SM, Klinge CM: Sex Differences in Estrogen Receptor Subcellular Location and Activity in Lung Adenocarcinoma Cells. Am J Respir Cell Mol Biol 2010, 42:320-330.
• [22]Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM: Activity and intracellular location of estrogen receptors [alpha] and [beta] in human bronchial epithelial cells. Mol Cell Endocrinol 2009, 205:12-21.
• [23]Watson CS, Jeng Y-J, Kochukov MY: Nongenomic Signaling Pathways of Estrogen Toxicity. Toxicol Sci 2010, 115:1-11.
• [24]Jeng Y-J, Kochukov M, Watson C: Membrane estrogen receptor-alpha-mediated nongenomic actions of phytoestrogens in GH3/B6/F10 pituitary tumor cells. J Mol Signal 2009, 4:2.
• [25]Wyckoff MH, Chambliss KL, Mineo C, Yuhanna IS, Mendelsohn ME, Mumby SM, Shaul PW: Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). J Biol Chem 2001, 276:27071-27076.
• [26]Kelly MJ, Levin ER: Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 2001, 12:152-156.
• [27]Levin ER: Minireview: Extranuclear Steroid Receptors: Roles in Modulation of Cell Functions. Mol Endocrinol 2011, 25:377-384.
• [28]Razandi M, Pedram A, Park ST, Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003, 278:2701-2712.
• [29]Zhang G, Liu X, Farkas AM, Parwani AV, Lathrop KL, Lenzner D, Land SR, Srinivas H: Estrogen Receptor Beta Functions through Non-genomic Mechanisms in Lung Cancer Cells. Mol Endocrinol 2009, 23:137-145.
• [30]Majidi M, Al-Wadei HA, Takahashi T, Schuller HM: Nongenomic beta estrogen receptors enhance beta1 adrenergic signaling induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human small airway epithelial cells. Cancer Res 2007, 67:6863-6871.
• [31]Levin ER: Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 2001, 91:1860-1867.
• [32]Audy MC, Vacher P, Duly B: 17 beta-estradiol stimulates a rapid Ca2+ influx in LNCaP human prostate cancer cells. Eur J Endocrinol 1996, 135:367-373.
• [33]Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz JL: A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology 1992, 131:1305-1312.
• [34]Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 1994, 91:8517-8521.
• [35]Le Mellay V, Grosse B, Lieberherr M: Phospholipase C beta and membrane action of calcitriol and estradiol. J Biol Chem 1997, 272:11902-11907.
• [36]Song RX, Santen RJ: Membrane initiated estrogen signaling in breast cancer. Biol Reprod 2006, 75:9-16.
• [37]Manavathi B, Kumar R: Steering estrogen signals from the plasma membrane to the nucleus: two sides of the coin. J Cell Physiol 2006, 207:594-604.
• [38]Filardo EJ: Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 2002, 80:231-238.
• [39]Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000, 14:1649-1660.
• [40]Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E: Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006, 12:6359-6366.
• [41]Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ: Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008, 70:165-190.
• [42]Prossnitz ER, Maggiolini M: Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 2009, 308:32-38.
• [43]Levin ER: G Protein-Coupled Receptor 30: Estrogen Receptor or Collaborator? Endocrinology 2009, 150:1563-1565.
• [44]Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, et al.: The G Protein–Coupled Receptor GPR30 Inhibits Proliferation of Estrogen Receptor–Positive Breast Cancer Cells. Cancer Res 2010, 70:1184-1194.
• [45]Langer G, Bader B, Meoli L, Isensee J, Delbeck M, Noppinger PR, Otto C: A critical review of fundamental controversies in the field of GPR30 research. Steroids 2010, 75:603-610.
• [46]Barton M: Position paper: The membrane estrogen receptor GPER/GPR30: Clues and questions. Steroids 2012, 77:935-942.
• [47]Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ: Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997, 45:607-617.
• [48]Feng Y, Gregor P: Cloning of a Novel Member of the G Protein-Coupled Receptor Family Related to Peptide Receptors. Biochem Biophys Res Commun 1997, 231:651-654.
• [49]Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, et al.: Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004, 64:9027-9034.
• [50]Masuda A, Kondo M, Saito T, Yatabe Y, Kobayashi T, Okamoto M, Suyama M, Takahashi T, Takahashi T: Establishment of Human Peripheral Lung Epithelial Cell Lines (HPL1) Retaining Differentiated Characteristics and Responsiveness to Epidermal Growth Factor, Hepatocyte Growth Factor, and Transforming Growth Factor β1. Cancer Res 1997, 57:4898-4904.
• [51]Al-Wadei HAN, Al-Wadei MH, Masi T, Schuller HM: Chronic exposure to estrogen and the tobacco carcinogen NNK cooperatively modulates nicotinic receptors in small airway epithelial cells. Lung Cancer 2010, 69:33-39.
• [52]Schuller HM, Al-Wadei HAN, Majidi M: Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma. Carcinogenesis 2008, 29:1979-1985.
• [53]Maiti K, Paul JW, Read M, Chan EC, Riley SC, Nahar P, Smith R: G-1-Activated Membrane Estrogen Receptors Mediate Increased Contractility of the Human Myometrium. Endocrinology 2011, 152:2448-2455.
• [54]Milligan G, Canals M, Pediani JD, Ellis J, Lopez-Gimenez JF: The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Found Symp Proc 2006, 2006:145-161.
• [55]Rios CD, Jordan BA, Gomes I, Devi LA: G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacology & Therapeutics 2001, 92:71-87.
• [56]Sandén C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J, Mårtensson UEA, Olde B, Leeb-Lundberg LMF: G Protein-Coupled Estrogen Receptor 1/G Protein-Coupled Receptor 30 Localizes in the Plasma Membrane and Traffics Intracellularly on Cytokeratin Intermediate Filaments. Mol Pharmacol 2011, 79:400-410.
• [57]Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O: GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. The Journal of steroid biochemistry and molecular biology 2010, 118:7-12.
• [58]Prossnitz ER, Barton M: The G-protein-coupled estrogen receptor GPER in health and disease. Endocrinology: Nature reviews; 2011.
• [59]Tu G, Hu D, Yang G, Yu T: The correlation between GPR30 and clinicopathologic variables in breast carcinomas. Technol Cancer Res Treat 2009, 8:231-234.
• [60]Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER: GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007, 196(386):e381-e389. discussion 386 e389-311
• [61]Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, Maggiolini M: The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006, 20:631-646.
• [62]Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER: GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 2009, 114:465-471.
• [63]Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Ando S, Maggiolini M: 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 2006, 70:1414-1423.
• [64]Luo HJ, Luo P, Yang GL, Peng QL, Liu MR, Tu G: G-protein Coupled Estrogen Receptor 1 Expression in Primary Breast Cancers and Its Correlation with Clinicopathological Variables. J Breast Cancer 2011, 14:185-190.
• [65]Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M: GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res Treat 2010, 123:51-58.
• [66]Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Oyan AM, Stefansson IM, Kalland KH, et al.: Loss of GPER identifies new targets for therapy among a subgroup of ERalpha-positive endometrial cancer patients with poor outcome. Br J Cancer 2012, 106:1682-1688.
• [67]Gao F, Ma X, Ostmann AB, Das SK: GPR30 Activation Opposes Estrogen-Dependent Uterine Growth via Inhibition of Stromal ERK1/2 and Estrogen Receptor Alpha (ERα) Phosphorylation Signals. Endocrinology 2011, 152:1434-1447.
• [68]Fasco MJ, Hurteau GJ, Spivack SD: Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002, 188:125-140.
• [69]Stabile LP, Siegfried JM: Sex and gender differences in lung cancer. J Gend Specif Med 2003, 6:37-48.
• [70]Siegfried JM, Hershberger PA, Stabile LP: Estrogen receptor signaling in lung cancer. Semin Oncol 2009, 36:524-531.
• [71]Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, Fritzemeier KH: G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 2008, 149:4846-4856.
• [72]Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, Wang ZY: Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010, 24:709-721.
• [73]Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, Schwarz G, Altmann H, Klewer M, Schoor M, et al.: GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod 2009, 80:34-41.
• [74]Ahola TM, Alkio N, Manninen T, Ylikomi T: Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Endocrinology 2002, 143:4620-4626.
• [75]Ahola TM, Manninen T, Alkio N, Ylikomi T: G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 2002, 143:3376-3384.
• [76]Ahola TM, Purmonen S, Pennanen P, Zhuang YH, Tuohimaa P, Ylikomi T: Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells. Eur J Biochem 2002, 269:2485-2490.
• [77]Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, Maggiolini M: G Protein-Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17{beta}-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells. Cancer Res 2007, 67:1859-1866.
• [78]Thomas P, Pang Y, Filardo EJ, Dong J: Identity of an Estrogen Membrane Receptor Coupled to a G Protein in Human Breast Cancer Cells. Endocrinology 2005, 146:624-632.
• [79]Giovannetti E, Erdem L, Olcay E, Leon LG, Peters GJ: Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Front Biosci 2011, 16:116-130.
• [80]Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G: American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol 2011.
• [81]Girgert R, Emons G, Grundker C: Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat 2012, 134:199-205.